Healthy men test drug interaction in Early-Stage trial
NCT ID NCT05550636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial looked at whether taking multiple doses of the experimental drug BI 1015550 (nerandomilast) changes how the body processes midazolam, a common sedative. Fifteen healthy men aged 18-55 took part. The goal was to see if BI 1015550 affects a key liver enzyme, which could matter for future patients taking other medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 1015550 (nerandomilast) and midazolam
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test